Jesús
San Miguel Izquierdo
Consultor Investigador
Complejo Hospitalario de Toledo
Toledo, EspañaPublicaciones en colaboración con investigadores/as de Complejo Hospitalario de Toledo (5)
2022
-
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852
2021
-
Pomalidomide, Cyclophosphamide, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma: Real-World Analysis of the Pethema-GEM Experience
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 6, pp. 413-420
2020
-
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality
Blood Cancer Journal, Vol. 10, Núm. 10
2019
-
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Blood, Vol. 134, Núm. 16, pp. 1337-1345
2001
-
Novel genomic imbalances in b-cell splenic marginal zone lymphomas revealed by comparative genomic hybridization and cytogenetics
American Journal of Pathology, Vol. 158, Núm. 5, pp. 1843-1850